PeptideDiary
A regimen tracker built specifically for injectable peptides: injection-site rotation, batch/lot numbers, bloodwork correlation, and side-effect logs — none of which generic med-trackers handle.
people currently self-administering peptides under a provider's guidance and frustrated by generic med trackers
- Injection-site map with rotation reminders based on last 7 sites used
- Per-peptide protocol tracking with cycle, dose, compounding pharmacy, and refill alerts
- Bloodwork-result timeline that overlays lab values against dosing changes
- Exportable treatment summary to share with prescribing clinicians
As peptides trend from gray-market to possibly-FDA-approved mainstream, self-administering users need legitimate tracking now and existing apps (Medisafe, Mango Health) don't handle injectables or the compounds actually in use.
Reddit threads explicitly ask 'how is everyone tracking their peptides' and Google Trends shows 2000+ searches for 'fda peptides', but most GLP-1/self-injector users appear to use spreadsheets or paper rather than seeking a dedicated app.How is everyone tracking their peptides : r/Peptides - Reddit ↗
Market is already saturated with at least 8–10 dedicated peptide trackers (PeptIQ, Peptly, Protocol, Peptide Tracker Cycle, DoseTrack, MyPepCalc, Pepio, Peptide Scholar) that already cover dose logging, site rotation, bloodwork, and reconstitution — directly contradicting the idea's premise.Best Peptide Tracker Apps 2026 — 10 Apps Compared | My Pep Calc ↗Best Peptide Tracker Apps 2026 — Free vs Paid Comparison | Regimen ↗
Subscription and lifetime-purchase models are validated in the niche (PeptIQ weekly/monthly/annual; Peptide Tracker Pro ~one-time), and the target user base already self-pays $300+/mo for GLP-1s, but free tiers from multiple competitors compress willingness to pay for a new entrant.Peptide App Pricing | PeptIQ Premium Plans | PeptIQ ↗Peptide Tracker: Cycle — Free Peptide Logbook ↗
FDA-approved peptide market is growing fast (~$49B by 2026, ~10% of new drug approvals 2020–2024), but compounding is being wound down (tirzepatide shortage resolved Dec 2024, semaglutide Feb 2025), pushing some use back behind providers — net effect on self-administering user base is uncertain.FDA-Approved Peptides: 2026 Status Tracker for Providers ↗FDA-Approved Peptide Drug List (Complete, Updated) ↗
Standard mobile app with HealthKit integration, reminders, CSV export, and local storage — features already implemented by multiple existing competitors — so technically straightforward but differentiation will require novel work beyond what incumbents ship.Peptide Tracker — Track Peptide Protocols, Doses & Injection Sites — Protocol App ↗